Biocept (NASDAQ: BIOC) and OmniComm Systems (OTCMKTS:OMCM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
This is a summary of recent recommendations and price targets for Biocept and OmniComm Systems, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility & Risk
Biocept has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, OmniComm Systems has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500.
Insider and Institutional Ownership
9.3% of Biocept shares are owned by institutional investors. 7.7% of Biocept shares are owned by insiders. Comparatively, 48.5% of OmniComm Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Biocept and OmniComm Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Biocept and OmniComm Systems’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Biocept||$3.22 million||6.78||-$18.39 million||($0.89)||-0.39|
|OmniComm Systems||$25.42 million||1.75||$100,000.00||$0.04||7.50|
OmniComm Systems has higher revenue and earnings than Biocept. Biocept is trading at a lower price-to-earnings ratio than OmniComm Systems, indicating that it is currently the more affordable of the two stocks.
OmniComm Systems beats Biocept on 8 of the 13 factors compared between the two stocks.
Biocept Company Profile
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
OmniComm Systems Company Profile
OmniComm Systems, Inc. is engaged in providing Web-based electronic data capture (EDC) and eClinical (eClinical) software and services that manage the clinical research process. The Company’s EDC and eClinical software and service offerings (eClinical Products or eClinical Solutions) consist of TrialMaster, TrialOne, Promasys, and eClinical Suite. Its eClinical Products allows clinical trial sponsors and investigative sites to collect, validate, transmit and analyze clinical study data. Its eClinical Products are designed to offer clinical trial sponsors the ability to conduct clinical trials under multiple platforms. It also provides business process consulting services that focus on integrating EDC, and an array of eClinical Solutions and processes into the clinical trial process. The Company operates through the delivery of EDC Software and services to clinical trial sponsors segment. Its services include hosting solutions, consulting services, customer support and training.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.